<DOC>
	<DOCNO>NCT02819583</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness CAR-T cell immunotherapy patient CD19 positive relapse refractory Leukemia Lymphoma .</brief_summary>
	<brief_title>CAR-T Cell Immunotherapy CD19 Positive Relapsed Refractory Leukemia Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic , B-Cell</mesh_term>
	<criteria>Male female subject CD19+ B cell malignancy patient available curative treatment option ( autologous allogeneic SCT ) limit prognosis ( several month &lt; 2 year survival ) currently available therapy enrol : 1 . Eligible disease : Acute lymphocytic leukemia ( ALL ) , Chronic lymphocytic leukemia ( CLL ) , Follicular lymphoma , Mantle cell lymphoma , Bcell prolymphocytic leukemia , diffuse large cell lymphoma , previously identify CD19+ . 2 . Patients 18 year age old , must life expectancy &gt; 12 week . 3 . Eastern cooperative oncology group ( ECOG ) performance status 02 karnofsky performance status ( KPS ) score high 60 . 4 . Adequate venous access apheresis venous sampling , contraindication leukapheresis . 5 . Females childbearing potential must negative pregnancy test subject must agree use effective method contraception two week last infusion CAR T cell . 6 . Adequate bone marrow , liver renal function assess follow laboratory requirement : White blood cell count ( WBC ) ≥ 2500c/ml , Platelets ≥ 50×10^9/L , Hb ≥ 9.0g/dL , lymphocyte ( LY ) ≥ 0.7×10^9/L , LY % ≥ 15 % , Alb ≥ 2.8g/dL , serum lipase amylase &lt; 1.5×upper limit normal , serum creatinine ≤ 2.5mg/dL , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 5×upper limit normal , serum total bilirubin ≤ 2.0mg/dL . These test must conduct within 7 day prior registration . 7 . Ability give inform consent . 1 . The transduction efficiency T cell less 30 % amplification T cell via artificial antigen present cell ( aAPC ) stimulation le 5 time . 2 . Pregnant nursing woman may participate . 3 . Active HIV , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection time screen . 4 . Serious illness medical condition would permit patient manage accord protocol , include active uncontrolled infection , major cardiovascular , coagulation disorder , respiratory immune system , myocardial infarction , cardiac arrhythmia , obstructive/restrictive pulmonary disease , psychiatric emotional disorder . 5 . History severe immediate hypersensitivity agent include cyclophosphamide , fludarabine , aldesleukin . 6 . Concurrent use systemic steroid . Recent current use inhale steroid exclusionary . 7 . Previously treatment gene therapy product . 8 . The existence unstable active ulcer gastrointestinal bleeding . 9 . Patients need anticoagulant therapy ( warfarin heparin ) . 10 . Patients need longterm antiplatelet therapy ( aspirin dose &gt; 300mg/d ; clopidogrel dose &gt; 75mg/d ) . 11 . Patients use fludarabine cladribine chemotherapy within 3 month prior leukapheresis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>